Residency · Birmingham, AL
Sponsored by University of Alabama Hospital
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
The New England journal of medicine · 2023 · 643 citations · Louis Nabors
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
Pediatric neurology · 2021 · 553 citations · Martina Bebin
Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline.
Neurology · 2023 · 167 citations · Lori Shutter
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
The New England journal of medicine · 2022 · 327 citations · Anthony Nicholas
Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms.
Nature communications · 2022 · 263 citations · Marissa Dean, David Standaert
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Neurology and therapy · 2023 · 115 citations · David Standaert
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
The Lancet. Neurology · 2024 · 126 citations · Rohit Dhall
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Neuro-oncology · 2023 · 210 citations · Louis Nabors